Ovarian Cancer Clinical Trials in Dallas

Showing 121-140 of 189 trials

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831

This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment. The primary study objective was to determine the maximum tolerated dose (MTD) and safety profile of the durvalumab and tremelimumab combination. Secondary objectives were to evaluate the pharmacokinetics (PK) and immunogenicity of durvalumab and tremelimumab, and the antitumor activity (tumor response, progression-free survival \[PFS\], and overall survival \[OS\]) of the durvalumab and tremelimumab combination. (Note: Collection of PK and immunogenicity samples was removed by amendment; analysis was not done.) Exploratory objectives were to evaluate the biological activity of the durvalumab and tremelimumab combination.

Breast CancerOvarian CancerColorectal Cancer+2 more

Ludwig Institute for Cancer Research104 participantsStarted Dec 2013

New Haven, Connecticut, United States • Boston, Massachusetts, United States • Buffalo, New York, United States +3 more locations

Active Not RecruitingPhase 2< 1 mile

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.

Ovarian CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more

ImmunoVaccine Technologies, Inc. (IMV Inc.)184 participantsStarted Dec 2018

Tucson, Arizona, United States • Los Angeles, California, United States • Boca Raton, Florida, United States +20 more locations

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Ovarian Cancer Trials in Other Cities

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of Ramucirumab in Ovarian Cancer

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Other Conditions in Dallas